SCHEMBL5955643

SCHEMBL5955643

CC1CC2CCN1C[C@@H]2NC(=O)n1cc(-c2ccc(F)cc2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.36
NTMT1 Q9BV86 1/20 0.35
TRPA1 O75762 1/20 0.35
CHRM3 P20309 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
DYRK1A Q13627 2/20 0.33
GSK3B P49841 1/20 0.33
PAX8 Q06710 1/20 0.33
MCHR1 Q99705 2/20 0.33
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
ROCK2 O75116 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5954836 0.91 USP30 (0.34) USP30DYRK1AGSK3BBRD4BRD2
SCHEMBL5955644 0.90 HTR3E (0.38) USP30BRD4BRD2BRD3ALDH1A1
SCHEMBL5955684 0.90 CHRNA7 (0.38) MCHR1BRD4BRD2BRD3NPC1
SCHEMBL5954762 0.89 MEN1 (0.38) CHRM3DYRK1APAX8DRD2DRD4
SCHEMBL5955673 0.88 CCNA2 (0.39) HRH3PAX8BRD4BRD2BRD3
SCHEMBL5954725 0.85 CHRNA7 (0.35) USP30DYRK1APAX8NPC1ALDH1A1
SCHEMBL5955680 0.84 KDM4E (0.35)
SCHEMBL5954741 0.84 CHRNA7 (0.37) NTMT1DYRK1AGSK3BBRD2DRD2
SCHEMBL5954818 0.83 CHRNA7 (0.41) ALDH1A1
SCHEMBL5374984 0.83 CHRM3 (0.48) NTMT1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060116395-A1 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease PFIZER INC 2006-06-01 US claimed
EP-1542999-A1 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY Pharmacia & Upjohn Company LLC (US) 2005-06-22 EP claimed
US-20040087616-A1 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease PIOTROWSKI DAVID W (US) 2004-05-06 US claimed
WO-2004013137-A1 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY PHARMACIA & UPJOHN COMPANY LLC (US) 2004-02-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116395-A1 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease CYP7B1, P2RX7, CYP3A7 USP30 4247/4885NTMT1 2733/4885TRPA1 2387/4885
US-20040087616-A1 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease CYP1B1, TPMT, CYP7B1 USP30 4397/4885NTMT1 2308/4885TRPA1 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.